Scarica l'app Stockscreener
0.96
5.88%
-0.06
Dopo l'orario di chiusura:
.95
-0.01
-1.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Pds Biotechnology Corp Borsa (PDSB) Ultime notizie
PDS Biotechnology Closes Financing and Retires Convertible Debentures - TipRanks
PDS Biotechnology (NASDAQ: PDSB) launches $50M ATM program tied to YA II financing - Stock Titan
[PRE 14A] PDS Biotechnology Corp Preliminary Proxy Statement - Stock Titan
PDS Biotechnology (NASDAQ: PDSB) adds $6M note and $50M at-the-market stock program - Stock Titan
PDS Biotechnology schedules 2026 annual meeting for Aug. 10; stockholder proposal deadline set - TradingView
PDS Biotechnology (PDSB) schedules 2026 annual meeting and sets June 25 proposal cutoff - Stock Titan
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher - MSN
Should I buy PDS Biotechnology (PDSB) - Zacks Investment Research
PDS Biotechnology Corporation - MLQ.ai
PDS Biotechnology Stock Gets Nasdaq Extension as Traders Eye PDSB - Bez Kabli
PDS Biotechnology (NASDAQ: PDSB) back in compliance with Nasdaq $1.00 bid rule - Stock Titan
PDS Biotechnology (PDSB) Slides 3.6% as Stock Tests Key Support Near $1.02Breakaway Gap - The Legal Advocate
PDSB Q4 2025 Earnings Call Transcript - Yahoo Finance
PDS Biotechnology Q1 2026 Earnings: EPS Beat on Narrower Loss, Clinical Progress in FocusReturn On Capital - Newser
PDS Biotechnology Q1 2026 Earnings: Narrowed Loss Per Share and Clinical Progress Drive Positive Market ResponseGrowth Acceleration Report - thelegaladvocate.com
PDS Biotechnology Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock Up 3.45%Earnings Growth Forecast - Newser
PDS Biotechnology Q1 2026 Earnings: EPS Beat Highlights Progress Despite Pre-Revenue StatusEarnings Forecast Report - newsline.com
PDS (PDSB) Q1 2026 Beat: Revenue $N/A, EPS Exceeds by SignificantPositive Surprise Momentum - The Legal Advocate
ETFs Investing in PDS Biotechnology Corp. Stocks - TradingView
PDS Biotechnology Q1 2026 earnings preview - MSN
Number of shareholders of PDS Biotechnology Corp. – SWB:EU6 - TradingView
PDS Biotechnology: Juni-Test für Wandelanleihe - kapitalmarktexperten.de
PDSB Stock Price, Quote & Chart | PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) - ChartMill
PDS Biotechnology Corp reports results for the quarter ended March 31Earnings Summary - TradingView
PDS Biotechnology (PDSB) posts Q1 2026 loss and plans costly debt redemption - Stock Titan
PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript - Sahm
PDS Biotech outlines VERSATILE-003 amendment targeting interim PFS with approximately 250 patients - MSN
PDSB Q1 2026 Earnings Transcript - AOL.com
PDS Biotechnology Q1 Earnings Call Highlights - MarketBeat
PDS Biotechnology Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
PDS Biotech Reports Q1 2026 Financial Results, Highlights Clinical Progress in Cancer Immunotherapy Trials - Minichart
Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations By Investing.com - Investing.com South Africa
PDSB: Protocol changes accelerate clinical timelines and reduce costs, with improved financials - TradingView
Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations - Investing.com
PDS Biotech (NASDAQ:PDSB) Posts Narrower Q1 Loss, Pre-Market Rises Over 5% - ChartMill
PDS Biotechnology posts quarterly financial results and updates clinical programs - Traders Union
PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings - Quiver Quantitative
PDS Biotechnology reports Q1 2026 net loss $7.3M, cash $21.7M; clinical updates on PDS0101 and PDS01ADC - TradingView
PDS Biotechnology Corporation Schedules Investor Webcast for Business and Clinical Update - Quiver Quantitative
PDS Biotechnology: Q1 Earnings Snapshot - marketscreener.com
PDSB: Q1 2026 featured clinical milestones, reduced net loss, and extended patent protection - TradingView
PDS Biotech (Nasdaq: PDSB) trims Q1 loss as R&D spending falls - Stock Titan
PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update - marketscreener.com
PDS Biotech trial reports 77.8% response in colorectal cancer - Stock Titan
TradingKey - TradingKey
PDS Biotechnology Pushes Toward Pivotal Cancer Trial Results With Cash in Focus - AD HOC NEWS
PDS Biotechnology Corp expected to post a loss of 15 cents a shareEarnings Preview - TradingView
PDS Biotechnology to provide quarterly results and clinical program progress - Traders Union
PDS Biotech to Discuss First Quarter 2026 Financial Results on May 6th - geneonline.com
PDS Biotech to give Q1 results and clinical update May 13 - Stock Titan
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):